Multi-asset income fund MATE rises on continued positive returns

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) published their ‘month in review’ for July 2021. 

Tim Mitchell, Investment Trust Client Director, at J.P. Morgan Asset Management, commented on the positive July performance of the trust and the economic outlook as the global reopening continues:

Month in review

The trust delivered a positive return on net assets in July.

Our equity exposure contributed positively to performance. Our bespoke equity sleeve – which is run by the International Equity Group – was the biggest positive contributor to performance. Our European small cap holding also provided a positive contribution, while our emerging markets exposure detracted.

Fixed income exposure was flat in aggregate, driven by our underweight duration positioning. Our short US treasury positioning through bond futures detracted from performance, whereas our long Euro Bund futures positioning generated positive returns. Our infrastructure exposure also generated small positive returns. From an asset allocation perspective we continued to reduce our exposure to high yield bonds and added to US equities.

Looking ahead

As the global reopening continues, we believe that while economic performance during the pandemic was defined by China and US exceptionalism, largely related to policy impulses, Western Europe is a more useful guide to post-pandemic growth dynamics. Consumers are powering a strong rebound in growth and still have plenty of firepower in their pockets, while policymakers continue to provide ample support.

We continue to see scope for risk assets to move higher over the course of the year, as pent-up demand is unleashed and rising sales offset higher input prices, albeit with higher volatility amid the spread of the Delta variant.

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) combines sustainable income and capital growth from globally diversified investments. The Trust aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Share on twitter
Share on linkedin

More articles like this

Analog Devices sees growth accelerating

Analog Devices expects annual revenue growth to average 7% to 10% over the next five years, the chip maker told analysts at a meeting Tuesday morning at the company’s headquarters near Boston. As the name implies, Analog Devices (ticker: ADI)

US FDA approves new Bristol Myers cancer immunotherapy

Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer. The company said it

‘Risk Assets will rally’ says JPMorgan Multi Asset Growth & Income fund

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) published their commentary for January 2022.  Month in review The trust delivered a negative return on net assets in January. Our equity allocation contributed negatively to overall performance as equity markets declined, driven by concerns

Procter & Gamble-owned Pantene partners with impressive female collective

THE WHAT? Procter & Gamble-owned Pantene has teamed up with ‘impressive, strong, modern, multi-hyphenate women’ to form the new Pantene Conditioner Collective. THE DETAILS Partners of the collective include Chloe Fineman, who features on Saturday Night Live and Dickinson, comedian Meg Stalter, and

Procter & Gamble’s sales jump

Shoppers shrugged off rising prices last year on products like Pampers diapers and Charmin toilet paper, Procter & Gamble said on Wednesday in announcing a jump in its second-quarter earnings. The consumer goods giant reported that price increases

Abbvie looks to crack the cystic fibrosis code

When it comes to cystic fibrosis Vertex is the undisputed heavyweight, but this has not stopped other groups from taking it on. Abbvie is the latest challenger, and data due this quarter could give clues about whether the

Italy to receive 40,000 Merck antiviral drug doses next week

Italy will receive around 40,000 doses of Merck & Co’s (MRK.N) COVID-19 antiviral drug next week, which will add to nearly 12,000 already distributed to hospitals, the special COVID-19 commissioner said on Sunday. “They are intended for clinical

No more posts to show